Related references
Note: Only part of the references are listed.A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies
G. I. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy
Sindura B. Ganapathi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2009)
The regulation of protein phosphorylation
Louise N. Johnson
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Simak Ali et al.
CANCER RESEARCH (2009)
Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics
Enrico Missner et al.
CHEMBIOCHEM (2009)
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity
Steven Howard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Matthew S. Squires et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
N. Raje et al.
LEUKEMIA (2009)
The rise of fragment-based drug discovery
Christopher W. Murray et al.
NATURE CHEMISTRY (2009)
CYCLIN-DEPENDENT KINASE 5 ACTIVATOR p35 OVER-EXPRESSION AND AMYLOID BETA SYNERGISM INCREASE APOPTOSIS IN CULTURED NEURONAL CELLS
E. Utreras et al.
NEUROSCIENCE (2009)
Identifying Tumor Cell Growth Inhibitors by Combinatorial Chemistry and Zebrafish Assays
Jing Xiang et al.
PLOS ONE (2009)
Apoptosis Is Essential for Neutrophil Functional Shutdown and Determines Tissue Damage in Experimental Pneumococcal Meningitis
Uwe Koedel et al.
PLOS PATHOGENS (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
Clifford D. Jones et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors
Clifford D. Jones et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Structure-guided discovery of cyclin-dependent kinase inhibitors
Thierry O. Fischmann et al.
BIOPOLYMERS (2008)
You never know: Cdk inhibitors as anti-cancer drugs
Tim Hunt
CELL CYCLE (2008)
Inhibitors of cyclin dependent kinases: Useful targets for cancer treatment
P. Sapra Sharma et al.
CURRENT CANCER DRUG TARGETS (2008)
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
Sonja Baumli et al.
EMBO JOURNAL (2008)
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
Janet S. Graham et al.
EUROPEAN JOURNAL OF CANCER (2008)
A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
D. Mahadevan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex
Aude Echalier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design
Paul G. Wyatt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases
S. H. Obligado et al.
KIDNEY INTERNATIONAL (2008)
High-throughput kinase profiling as a platform for drug discovery
David M. Goldstein et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
Shudong Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
Elisabeth I. Heath et al.
INVESTIGATIONAL NEW DRUGS (2008)
The functional role of an interleukin 6-inducible CDK9•STAT3 complex in human γ-fibrinogen gene expression
Tieying Hou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Flavopiridol in the treatment of chronic lymphocytic leukemia
Beth A. Christian et al.
CURRENT OPINION IN ONCOLOGY (2007)
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
M. N. Fornier et al.
CLINICAL CANCER RESEARCH (2007)
Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases
Karima Bettayeb et al.
CANCER RESEARCH (2007)
An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins
Vassilios Myrianthopoulos et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo
Kohsuke Kitani et al.
JOURNAL OF PHYSIOLOGICAL SCIENCES (2007)
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia
Judith E. Karp et al.
CLINICAL CANCER RESEARCH (2007)
Cell-cycle control and cortical development
Colette Dehay et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Multiple levels of cyclin specificity in cell-cycle control
Joanna Bloom et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine
Nikolay O. Bukanov et al.
NATURE (2006)
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors:: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects
Vladimir Krystof et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
Wanda DePinto et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis
Adriano G. Rossi et al.
NATURE MEDICINE (2006)
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells
Christopher J. Strock et al.
CANCER RESEARCH (2006)
Protein kinase resource: An integrated environment for phosphorylation research
RH Niedner et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2006)
CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads
G Castanedo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo
OM Tirado et al.
CANCER RESEARCH (2005)
Roscovitine targets, protein kinases and pyridoxal kinase
S Bach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin
HS Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Pharmacological inhibitors of cyclin-dependent kinases
M Knockaert et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Share Paper
